20569442

Source:http://linkedlifedata.com/resource/pubmed/id/20569442

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0017262, umls-concept:C0025723, umls-concept:C0030705, umls-concept:C0086860, umls-concept:C0185117, umls-concept:C0525037, umls-concept:C1880022, umls-concept:C2239176, umls-concept:C2911684
pubmed:dateCreated	2010-7-19
pubmed:abstractText	The product of CDKN2A, p16 is an essential regulator of the cell cycle controlling the entry into the S-phase. Herein, we evaluated CDKN2A promoter methylation and p16 protein expression for the differentiation of hepatocellular carcinoma (HCC) from other liver tumors.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-10421671, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-10518306, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-10518307, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-10705239, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-10734209, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-10897001, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-11016622, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-11040180, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-11106567, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-11171828, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-12565176, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-12721245, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-12963980, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-13160935, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-14598358, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-14623619, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-14667750, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-15569978, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-16207479, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-6118576, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-7585152, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-8153634, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-8620534, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-8781327, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-8790415, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-9049204, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-9185756, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-9244355, http://linkedlifedata.com/resource/pubmed/commentcorrection/20569442-9922321
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100967800
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase Inhibitor..., http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
pubmed:status	MEDLINE
pubmed:issn	1471-2407
pubmed:author	pubmed-author:CsepregiAntalA, pubmed-author:EbertMatthias PaMP, pubmed-author:HoffmannJulianeJ, pubmed-author:MalfertheinerPeterP, pubmed-author:RöckenChristophC, pubmed-author:RoessnerAlbertA, pubmed-author:Schneider-StockRegineR, pubmed-author:SchulzHans-UlrichHU
pubmed:issnType	Electronic
pubmed:volume	10
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	317
pubmed:dateRevised	2010-9-30
pubmed:meshHeading	pubmed-meshheading:20569442-Adult, pubmed-meshheading:20569442-Aged, pubmed-meshheading:20569442-Aged, 80 and over, pubmed-meshheading:20569442-Carcinoma, Hepatocellular, pubmed-meshheading:20569442-Cyclin-Dependent Kinase Inhibitor p16, pubmed-meshheading:20569442-DNA Methylation, pubmed-meshheading:20569442-Epigenesis, Genetic, pubmed-meshheading:20569442-Female, pubmed-meshheading:20569442-Gene Expression Regulation, Neoplastic, pubmed-meshheading:20569442-Humans, pubmed-meshheading:20569442-Immunohistochemistry, pubmed-meshheading:20569442-Liver Neoplasms, pubmed-meshheading:20569442-Male, pubmed-meshheading:20569442-Middle Aged, pubmed-meshheading:20569442-Polymerase Chain Reaction, pubmed-meshheading:20569442-Promoter Regions, Genetic, pubmed-meshheading:20569442-Tumor Markers, Biological
pubmed:year	2010
pubmed:articleTitle	Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma.
pubmed:affiliation	Department of Gastroenterology, Hepatology, and Infectious Diseases, Otto-von-Guericke University, 39120 Magdeburg, Germany. csepregia@yahoo.de
pubmed:publicationType	Journal Article